In contrast, in MCI/AD, temporal tau PET BPND was associated with worse cross-sectional performance on the MMSE (β = −0.45, FDR P < 0.01) and with a steeper rate of decline on the MMSE (β = −0.17, FDR P < 0.01) and on the CFT animals test (β = −0.10, FDR P = 0.04) (Fig. 3). The gene discussed is MAPT; the disease is Alzheimer disease.